FDA Clears AstraZeneca's COVID-19 Antibody Treatment For Immunocompromised (nbcnews.com) 13
The Food and Drug Administration authorized the first injectable monoclonal antibody cocktail for long-term prevention of Covid-19 among people with weakened immune systems before they have been exposed to the coronavirus. NBC News reports: The FDA issued an emergency use authorization Wednesday for AstraZeneca's antibody cocktail, Evusheld, for what is known as pre-exposure prophylaxis, or PrEP, against Covid-19. To date, such laboratory-produced antibodies have been authorized only as early treatment of Covid-19 or as preventive therapy for high-risk people immediately after close contact with someone who has tested positive.
Evusheld can be used as PrEP by people ages 12 and older who are moderately to severely immunocompromised and may not get adequate immune responses from a Covid vaccine. The therapy is also an option for the rare people who have histories of severe adverse reactions to a Covid vaccine or its components. The AstraZeneca therapy involves getting preventive injections as often as every six months. According to a large placebo-controlled clinical trial, the cocktail is about 83 percent effective at preventing symptomatic disease during such an interval. It's unclear how the highly mutated omicron variant of the coronavirus -- which is spreading in 57 countries, including the U.S. -- might affect the efficacy of the monoclonal antibody therapy.
Evusheld can be used as PrEP by people ages 12 and older who are moderately to severely immunocompromised and may not get adequate immune responses from a Covid vaccine. The therapy is also an option for the rare people who have histories of severe adverse reactions to a Covid vaccine or its components. The AstraZeneca therapy involves getting preventive injections as often as every six months. According to a large placebo-controlled clinical trial, the cocktail is about 83 percent effective at preventing symptomatic disease during such an interval. It's unclear how the highly mutated omicron variant of the coronavirus -- which is spreading in 57 countries, including the U.S. -- might affect the efficacy of the monoclonal antibody therapy.
Re: (Score:1)
Probably, but I don't think anyone knows how to do it yet, at least not safely.
Ah (Score:4, Insightful)
The AstraZeneca therapy involves getting preventive injections as often as every six months.
So, really, not unlike the current frequency of recommended vaccine shots.
Re: (Score:3)
And it must be safe to assume it contains a similar amount of Bill Gates' 5G microchips / alien DNA / UN time-delayed sterilization serum as the vaccines of course :-P
Re: (Score:2)
Re: (Score:2)
Debunking the idea that this suggests that the vaccines are dangerous in any way:
https://healthfeedback.org/cla... [healthfeedback.org]
Also do you know what else will get things like the COVID19 spike protein into your body? An actual COVID19 infection.
bleach enemas (Score:2)
And it must be safe to assume it contains a similar amount of Bill Gates' 5G microchips / alien DNA / UN time-delayed sterilization serum as the vaccines of course :-P
Bill Gates' butthole microchips are a much better alternative than bleach enemas (the stuff to, literally, die for). Really, not the onion: link to story here. [unionesarda.it]
Re: (Score:2)
The AstraZeneca therapy involves getting preventive injections as often as every six months.
So, really, not unlike the current frequency of recommended vaccine shots.
Except, we've been using antibody treatments since the 90's at the very latest, while transgenic vector/mRNA vaccines have been used in humans since...?
Re: (Score:1)
Sure, but the marketing advantage is that it's not called vaccine anymore, as that name was found to cause unexplainable adverse reactions in certain parts of the population.
Mutation risk? (Score:2)
I'm really interested in what the mutation risk is here. If mutations happen in people who are surviving on their own immune system they are normally already in the process of fighting the virus. Their bodies will already be able to kill off a very closely related virus so that they will continue to be able to kill the mutant whilst also developing antibodies that clear out the mutant. If a mutation happens in an immunocompromised patient, especially from an escape variant, there will be no new antibodie
Re: (Score:1)
Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful pathogens such as viruses. Tixagevimab and cilgavimab are long-acting monoclonal antibodies that are specifically directed against the spike protein of SARS-CoV-2, designed to block the virus’ attachment and entry into human cells. Tixagevimab and cilgavimab bind to different, non-overlapping sites on the spike protein of the virus.
Seems they are hoping a mutation wouldn't develop fast enough to evade both quickly enough.
It's also not authorised for people who are already infected, or are close contacts of infected people.
The product is only authorized for those individuals who are not currently infected with the SARS-CoV-2 virus and who have not recently been exposed to an individual infected with SARS-CoV-2
Lets hope they are right. And it doesn't turn into gain of function research.